for lowering post-prandial blood glucose levels in people with diabetes mellitus.
Description
Voglibose is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. Voglibose delays the absorption of glucose thereby reduces the risk of macrovascular complications. Voglibose is a research product of Takeda Pharma, a Japan-based company.
Postprandial hyperglycemia (PPHG) is primarily due to first phase insulin secretion. Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal.
Find new trading partners and manage your transactions through every step of the Pharmaceutical supply chain from Quoting to Shipping. Whether you're a buyer or a supplier the iOPharma platform will benefit your organisation.
